Enhancement of fibrinolysis by a factor XA inhibitor edoxaban and combination with an inhibitor of activated thrombin-activatable fibrinolysis inhibitor in vitro

被引：0
|
作者：
Morishima, Y. [1 ]
Kamisato, C. [1 ]
Furugohri, T. [1 ]
机构：
[1] Daiichi Sankyo Co Ltd, Biol Res Labs, Tokyo, Japan
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO353-MON
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
  • [31] A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor
    Yoshiyuki Morishima
    Yuko Honda
    Journal of Thrombosis and Thrombolysis, 2019, 48 : 103 - 110
  • [32] Prolongation of clot lysis time by a direct thrombin inhibitor: involvement of thrombin generation enhancement and thrombin-activatable fibrinolysis inhibitor
    Morishima, Y.
    Kamisato, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 672 - 673
  • [33] Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor
    Sanglas, L.
    Arolas, J. L.
    Valnickova, Z.
    Aviles, F. X.
    Enghild, J. J.
    Gomis-Ruth, F. X.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (05) : 1056 - 1065
  • [34] Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system
    Suzuki, Yuko
    Sano, Hideto
    Mochizuki, Liina
    Honkura, Naoki
    Urano, Tetsumei
    BLOOD ADVANCES, 2020, 4 (21) : 5501 - 5511
  • [35] Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
    Zhao, L
    Morser, J
    Bajzar, L
    Nesheim, M
    Nagashima, M
    THROMBOSIS AND HAEMOSTASIS, 1998, 80 (06) : 949 - 955
  • [36] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Eichinger, S
    Schönauer, V
    Weltermann, A
    Minar, E
    Bialonczyk, C
    Hirschl, M
    Schneider, B
    Quehenberger, P
    Kyrle, PA
    BLOOD, 2004, 103 (10) : 3773 - 3776
  • [37] Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension
    Yaoita, Nobuhiro
    Satoh, Kimio
    Satoh, Taijyu
    Sugimura, Koichiro
    Tatebe, Shunsuke
    Yamamoto, Saori
    Aoki, Tatsuo
    Miura, Masanobu
    Miyata, Satoshi
    Kawamura, Takeshi
    Horiuchi, Hisanori
    Fukumoto, Yoshihiro
    Shimokawa, Hiroaki
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (06) : 1293 - +
  • [38] Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma
    Fujiwara, Atsushi
    Taguchi, Osamu
    Takagi, Takehiro
    D'Alessandro-Gabazza, Corina N.
    Boveda-Ruiz, Daniel
    Toda, Masaaki
    Yasukawa, Atsushi
    Matsushima, Yuki
    Miyake, Yasushi
    Kobayashi, Hiroyasu
    Kobayashi, Tetsu
    Gil-Bernabe, Paloma
    Naito, Masahiro
    Yoshida, Masamichi
    Morser, John
    Takei, Yoshiyuki
    Gabazza, Esteban C.
    LUNG, 2012, 190 (02) : 189 - 198
  • [39] Isolation and characterization of a murine thrombin-activatable fibrinolysis inhibitor (TAFI).
    Conway, EM
    Ong, K
    Steiner-Mosonyi, M
    Bajzar, L
    Schuh, AC
    BLOOD, 1998, 92 (10) : 94B - 94B
  • [40] The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing
    Verkleij, Chantal J. N.
    Roelofs, Joris J. T. H.
    Havik, Stefan R.
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS RESEARCH, 2010, 126 (05) : 442 - 446
12345